Part 5 of the article series on the Biomarker Workshop 2025

The treatment of people with autism and/or ADHD has changed fundamentally in recent years. Away from fighting symptoms, towards a holistic approach that understands neurodiversity as a natural variation of human neurology.

The new paradigm: acceptance instead of normalisation

Attwood and Garnett describe a fundamental shift in therapy:

  • No longer: “Repairing” the core symptoms of autism and ADHD with psychological, speech or occupational therapy
  • Instead: Embracing neurodiversity (self-acceptance) for greater mental well-being and quality of life

This is achieved by:

  • Increasing self-awareness and self-acceptance
  • Treating co-occurring mental health conditions
  • Caring for the physical body
  • Providing support and accommodations

Medication in AuDHD: caution required

Research shows that standard ADHD medication works differently in autistic people:

  • Methylphenidate (Ritalin, Concerta): 73% positive response rate in children with ADHD, but only 49% in autistic children with ADHD (King et al., 2020)
  • Guanfacine (Intuniv): 34–50% response rate in autism plus ADHD (Scahill et al., 2015)

The recommendation: in autistic people with ADHD, caution is required. Medication should be carefully adjusted and monitored.

Physical exercise and mindfulness

Physical exercise has a proven positive effect on executive functions. A study by Tse et al. (2025) in the journal “Autism” shows that cycling (mobile and stationary) leads to significant improvements.

Mindfulness demonstrably changes the brain. A meta-analysis of 123 studies (Fox et al., 2015) identified 8 brain regions that are consistently altered by daily mindfulness practice – all relevant to ADHD and/or autism.

Recommended approaches:

  • Mind-body practices: yoga, meditation, tai chi, taekwondo
  • Acceptance and Commitment Therapy (ACT)
  • Compassion Focused Therapy (CFT)
  • Dialectical Behaviour Therapy (DBT)
  • Internal Family Systems (IFS)

Diagnosis as a turning point

Attwood and Garnett emphasise that the diagnosis is a decisive event for identity formation. They prefer the term “discovery” to “diagnosis” because it emphasises the positive aspect: finally understanding why one is different.

Research by Cooper, Smith and Russell (2017) shows that, although autistic people report mental health problems more often, a positive autistic social identity offers a protective factor.

What helps:

  • Fostering positive autistic identities
  • Positive online community support that focuses on strengths
  • Self-help groups that enable personal exchange and emphasise strengths

Recognising and using strengths

Common ADHD strengths:

Visual thinking, “big picture” thinking, creativity, energy, humour, courage, spontaneity, charisma, hyperfocus, connection with others

Common autistic strengths:

Visual and verbal abilities, creative thinking, monotropism, compassion, logic, honesty, a sense of social justice, pattern recognition, systems thinking, long-term memory, attention to detail, deep connections

Strengths in AuDHD – the symbiosis:

  • Innovative and creative problem-solving
  • Hyperfocused engagement
  • Persistence combined with adaptability
  • Passion with energy
  • Heightened perception and sensory awareness

Understanding and explaining neurodiversity

Attwood and Garnett recommend explaining autism and ADHD as follows:

  • A different way of feeling, thinking, learning and relating
  • Based on a different neurology
  • There are many different ways of being autistic or having ADHD
  • With advantages and disadvantages
  • Being misunderstood is often a disadvantage
  • Knowing one’s own neuroprofile helps

Find out more at the Biomarker Workshop 2025

On 11 December 2025, Matthias Huber will give his talk “Understanding therapy from within: how a therapist’s own lived experience decisively shapes autism treatment”.

Source: handout “Understanding Autism and ADHD” by Prof. Tony Attwood & Dr Michelle Garnett, 2025

This is part 5 and the conclusion of the article series based on the handout by Prof. Tony Attwood and Dr Michelle Garnett for the Biomarker Workshop 2025.